Comments
Dr Reddy’s Laboratories Ltd has announced the settlement of its litigation with Celgene, a wholly-owned subsidiary of Bristol Myers Squibb, relating to patents for Revlimid (lenalidomide) capsules.
In a settlement of all outstanding claims in the litigation, Celgene has agreed to provide Dr Reddy’s with a licence to sell volume-limited amounts of generic lenalidomide capsules in the US after March 2022 subject to regulatory approval.
The agreed-upon percentages are confidential, the Hyderabad-based pharma company stated.
Dr Reddy’s is also licensed to sell generic lenalidomide capsules in the US without volume limitation beginning on January 31, 2026.
“We are pleased with the settlement agreement, and look forward to bringing a generic version of lenalidomide to market soon subject to regulatory approval for the benefit of patients,” said Marc Kikuchi, CEO, North America Generics, Dr Reddy’s Laboratories.
Revlimid is a trademark of Celgene, a wholly-owned subsidiary of Bristol Myers Squibb.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.